Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
The sodium glucose co-transporter 2 (SGLT2) functions in the proximal tubule to reabsorb the bulk of filtered glucose. SGLT2 inhibitors have been developed to promote renal glucose excretion to improve glycemic control in diabetes. Regulatory guidance mandated adequately powered studies to detect in...
Saved in:
Main Authors: | Gilda M. Portalatin, Irene Hong-McAtee, Anna M. Burgner, Edward R. Gould, Tracy E. Hunley |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Pediatrics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2025.1521425/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Association of SGLT-2 inhibitors (Empagliflozin) with the development of hypernatremic dehydration: a case report
by: Diana Alegre-González, et al.
Published: (2025-10-01) -
Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease
by: Supattra Hunsuwan, et al.
Published: (2025-01-01) -
Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production
by: Yan Tian, et al.
Published: (2025-12-01) -
A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand
by: Natthakan Chitpim, et al.
Published: (2025-01-01) -
Comprehensive management application of sulodexide on proteinuria: 2 case reports
by: Li Zhou, et al.
Published: (2025-02-01)